- Home
- SLQT vs ENTX Comparison
SLQT vs ENTX Comparison
Compare SLQT & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLQT | ENTX |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.7M | 147.4M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SLQT | ENTX |
|---|---|---|
| Price | $0.73 | $2.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.88 | ★ $9.00 |
| AVG Volume (30 Days) | 733.5K | ★ 3.6M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.00 | N/A |
| EPS | 0.11 | ★ 0.22 |
| Revenue | ★ $1,526,594,000.00 | $42,000.00 |
| Revenue This Year | $10.97 | N/A |
| Revenue Next Year | $6.14 | N/A |
| P/E Ratio | ★ $6.49 | $13.05 |
| Revenue Growth | ★ 15.50 | N/A |
| 52 Week Low | $0.56 | $0.91 |
| 52 Week High | $2.77 | $4.20 |
Technical Indicators
Market Signals| Indicator | SLQT | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | 57.95 |
| Support Level | $0.64 | $1.10 |
| Resistance Level | $0.79 | $3.22 |
| Average True Range (ATR) | 0.06 | 0.32 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 40.44 | 13.81 |
Price Performance
Historical ComparisonAbout SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.